Fu Xiumei, Zheng Yangming, Lin Chunyu, Wang Ping, Wang Changyun
School of Economics, Ocean University of China, Qingdao, 266100 China.
Business School, Qingdao University, Qingdao, 266100 China.
J Ocean Univ China. 2023;22(1):271-284. doi: 10.1007/s11802-023-5310-5. Epub 2022 Aug 22.
The marine biopharmaceutical industry (MBI) has been considered as an important part of the blue economy. The high-quality development of this industry depends on the high-level coordinated development of technological innovation system (TIS). In the present study, the coupling mechanism of industrial innovation input subsystem and innovation output subsystem was analyzed for the first time. On this basis, the development level and coupling coordination level of TIS in China's MBI during 2008-2018 were empirically evaluated with the capacity coupling coordination model. Then, the obstacle factors were diagnosed and recognized with the obstacle model. The results showed that the innovation input index fluctuated at a low level in China's MBI. The innovation output index has basically maintained a growth trend, whereas the quality of development was not high. Although the coupling coordination level of TIS showed a positive change as mild disordered → primary coordinated → well-coordinated, the development type of innovation system has changed from the lagging output of innovation into the lagging input of innovation. Insufficient input of innovation factors remained the main obstacle to the improvement of coordination level. Based on the above analysis, suggestions were put forward from the perspectives of policy and fund guarantees to improve the coupling coordination level in China's MBI.
海洋生物制药产业（MBI）被视为蓝色经济的重要组成部分。该产业的高质量发展依赖于技术创新系统（TIS）的高水平协调发展。在本研究中，首次分析了产业创新投入子系统与创新产出子系统的耦合机制。在此基础上，运用容量耦合协调模型对2008 - 2018年中国海洋生物制药产业技术创新系统的发展水平和耦合协调水平进行了实证评估。然后，运用障碍模型对障碍因素进行了诊断和识别。结果表明，中国海洋生物制药产业的创新投入指数在低水平波动。创新产出指数基本保持增长趋势，但其发展质量不高。虽然技术创新系统的耦合协调水平呈现出从轻度失调→初级协调→良好协调的积极变化，但创新系统的发展类型已从创新产出滞后转变为创新投入滞后。创新要素投入不足仍是协调水平提升的主要障碍。基于上述分析，从政策和资金保障角度提出了提高中国海洋生物制药产业耦合协调水平的建议。
